BRCA2 Mutation Carrier
20
0
3
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.0%
1 terminated out of 20 trials
92.9%
+6.4% vs benchmark
10%
2 trials in Phase 3/4
23%
3 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (20)
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy
Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries